Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: Pain Therapeutics, Inc. (PTIE)

No earlier versions found for this Subject.

Return to Pain Therapeutics, Inc. (PTIE)

Recently PTIE closed a deal with King Pharmaceuticals on its abuse resistent opioid pain killer, Remoxy, and on 1/4/06 was paid $150 M. The deal could bring as much as $400 M plus royalties. PTIE also has Oxytrex, an opioid pain killer that has fewer side effects and fewer withdrawal complications than other opioid pain killers. A recent Oxytrex P III trial was under powered for the desired indication and PTIE must now design a new P III which should get this drug approved. Plenty of money and good prospects.